PD-L1 inhibition in NSCLC cell lines was achieved at a micromolar dosage, using both JQ1 or OTX015, and was in line with the induced inhibition of other BRD4 targets, such as c-MYC (only for H1299 cells), RUNX2, COL1A1 and RAD51 (Suppl. The gene discussed is RAD51; the disease is non-small cell lung carcinoma.